1 / 22

Rosiglitazone and Mortality in Chronic Hemodialysis Patients in the DOPPS

Rosiglitazone and Mortality in Chronic Hemodialysis Patients in the DOPPS. When Using DOPPS Slides. DOPPS Slide Use Guidelines. Introduction. Introduction (cont.). DOPPS Background (1). DOPPS Background (2). Methods. Methods (cont.). Methods (cont.). Methods. Results.

zita
Download Presentation

Rosiglitazone and Mortality in Chronic Hemodialysis Patients in the DOPPS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Rosiglitazone and Mortality in Chronic Hemodialysis Patients in the DOPPS

  2. When Using DOPPS Slides

  3. DOPPS Slide Use Guidelines

  4. Introduction

  5. Introduction (cont.)

  6. DOPPS Background (1)

  7. DOPPS Background (2)

  8. Methods

  9. Methods (cont.)

  10. Methods (cont.)

  11. Methods

  12. Results

  13. Table 1. Descriptive measures of the sample, by medication type

  14. Table 1. Descriptive measures of the sample, by medication type (cont.)

  15. Table 2. Descriptive characteristics of patients by facility quartile of rosiglitazone use

  16. Table 2. Descriptive characteristics of patients by facility quartile of rosiglitazone use (cont.)

  17. Results

  18. Table 3. Patient-level and facility-level mortality models

  19. Figure 1. Adjusted cumulative all-cause mortality by medication type

  20. Figure 2. Adjusted all-cause mortality by facility-practice quartile of patients prescribed rosiglitazone among OHA-treated patients

  21. Conclusions

  22. Acknowledgements

More Related